KALAMAZOO, Mich., Nov. 21, 2014 /PRNewswire/ -- Innovative Cardiovascular Solutions, LLC, a privately-held clinical stage company headquartered in Kalamazoo, MI, announced today that it has completed a Class A Unit financing totaling $5.0 million to fund its novel Emblok™ Embolic Protection Catheter that has been designed to be utilized in Trans Aortic Valve Replacement (TAVR) procedures as well as several other left heart interventional procedures where embolic protection would be required. The round included robust participation by cardiovascular experts and multiple angel investors. "Innovative Cardiovascular Solutions has made tremendous progress in the last 18 months since its inception with the design and development of the Emblok Embolic Protection Catheter and expects to perform First-in-Man studies in the first half of 2015," remarked R. Kevin Plemmons, its CEO.
Innovative Cardiovascular Solutions (ICS) is pleased to introduce the Emblok Embolic Protection Catheter to the medical device community. The Emblok device is the world's first and only embolic protection device that offers full circumferential aortic collection while protecting the cerebral, abdominal and peripheral vasculature from embolic debris. The unique design of the Emblok system allows the physician constant visualization during the procedure and aids in precise valve implantation while eliminating the need for constant dye injections to verify positioning.
"We are delighted by the strong vote of confidence from our investors supporting our pursuit of this innovative and comprehensive approach to embolic protection," stated Mr. Plemmons. "We believe this unique technology which is intuitive and easy to use will have a significant impact in the area of embolic protection to help minimize stroke and neurocognitive issues associated with TAVR and other left heart interventional procedures."
ICS was founded by William Merhi, DO, an interventional cardiologist specializing in structural heart procedures. Mr. Plemmons is a recognized medical start-up device entrepreneur with extensive experience in the field of interventional cardiology.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in this offering. There will not be any sale of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. ICS's actual results may differ materially from ICS's historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to ICS's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for its products and for the pursuit of new product opportunities, ability to hire required personnel, the risk of whether products result from development activities, protection of ICS's intellectual property portfolio, the risk associated with obtaining the necessary regulatory approvals, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other potential factors.
For more information:
R. Kevin Plemmons
SOURCE Innovative Cardiovascular Solutions, LLC